Four brands but no MabThera in Indian rituximab market flux
This article was originally published in Scrip
Executive Summary
Evolving strategies and competition appear to have contributed to significant tweaks on the Indian market for rituximab – currently in the spotlight with the entry of the local firm, Intas, with its biosimilar version of the monoclonal antibody.